Two weeks ago, Amarantus BioSciences Inc. (AMBS) issued a PR announcing positive behavioural efficacy data for their fight against Parkinson’s disease. Since then, when just 3 million shares were trading at a high of 0.0065, AMBS stock price has exploded exponentially gaining 764% in the process. Had it not been for patience and prior knowledge that any good news on a biotech / pharmaceutical company was going to lead to a positive share price, many traders (who we dedicate tonight’s first beer to) would be kicking themselves for having sold too early.
Click HERE To Make Sure You Don’t Miss Any Of Our Breaking Alerts!
AMBS Stock Chart
Market Cap: 5.57M
Last: 0.0515, up 0.0235 (83.93%)
Dollar Volume: $1,676,649
Average Trade Size: 27,434
Issued and Outstanding: 108,241,988
Looking for Hot Penny Stocks?
Click here and get Alerts on the Best Penny Stocks FREE
Although the Company has had no revenues thus far in 2012, last year, Amarantus was able to book $178,308 in grant money received during the first six months of 2011. This is very promising considering that the Company’s lead program, MANF, showed better results in a neurorestoration 6-hydroxydopamine (6-OHDA) rat model of Parkinson’s disease compared to GDNF, a neurotrophic factor currently in a Phase 2 clinical trial as a disease-modifying treatment for Parkinson’s disease.
MANF/GDNF – it means the Company says their treatment methods are better than the competitor which is further along already. MANF is a highly potent, neurotrophic factor currently in pre-clinical development for the treatment of several apoptosis-related disorders.
MANF is an endogenous, highly-conserved, ubiquitously expressed and highly potent secreted human growth factor up-regulated in the adaptive pathway of the Unfolded Protein Response resulting in the prevention of apoptosis. This cell death is associated with several devastating human diseases and injury related disorders. By mediating this critical biological process, MANF is highly indicated for the treatment of several poorly served medical conditions, including Parkinson’s disease and Ischemic Heart Disease.
Translation: AMBS is Gooooooood!
About AMBS Stock
Amarantus BioSciences, Inc. is a development stage biopharmaceutical drug development company dedicated to discovering and sourcing high-potential bioscience platform technologies and developing them towards commercialization. Through June 30, 2012, the Company has been primarily engaged in biotechnology research and development and raising capital.
Click here to view the SEC filings for AMBS.
Bottom Line: AMBS very well could be the hottest penny stock since people in North America began hearing the name “Sandy” on the television. Although AMBS stock and the superstorm have nothing in common other than the massive force they have had on the markets, traders should watch this closely for updates which have obviously had huge impacts on the PPS. Congrats to all those who found this penny stock and got in early.
Here is your opportunity to subscribe to the Most Read Penny Stock Newsletter
If You Can’t Make Money With Us, You Shouldn’t Be Trading Penny Stocks
(We are 100% Anti-Spam and will never rent or sell your information)Share